# US 2001/0034329 A1 · Antisense modulation of focal adhesion kinase expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034329 A1
- Document ID: US20010034329A1
- Status: Published application
- Kind: A1
- Application number: 09/757,100
- Filed: 2001-01-09
- Published: 2001-10-25
- Earliest claimed: 1999-08-19
- Inventors: Brett P. Monia; William A. Gaarde; Pamela S. Nero
- Web page: https://patentgrep.com/patent/US20010034329A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.

## Claims

### Claim 1

An antisense compound 8 to 30 nucleobases in length targeted to the 5′-untranslated region, translational termination region or 3′ untranslated region of a nucleic acid molecule encoding focal adhesion kinase, wherein said antisense compound inhibits the expression of said focal adhesion kinase.

### Claim 2 (depends on 1)

The antisense compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 3, 4, 6, 7, 8, 9, 16, 17, 18, 20 or 23.

### Claim 4 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 5 (depends on 4)

The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 6 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 7 (depends on 6)

The antisense compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl moiety.

### Claim 8 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 9 (depends on 8)

The antisense compound of claim 8 wherein the modified nucleobase is a 5-methyl cytosine.

### Claim 10 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11 further comprising a chemotherapeutic agent.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14 wherein the chemotherapeutic agent is 5-fluorouracil.

### Claim 16 (depends on 14)

A method of inhibiting the growth of a tumor in an animal comprising administering to said animal an effective amount of the pharmaceutical composition of claim 14.

### Claim 17 (depends on 1)

A method of inhibiting the expression of focal adhesion kinase in cells or tissues comprising contacting said cells or tissue with the antisense compound of claim 1 so that expression of focal adhesion kinase is inhibited.

### Claim 18

An antisense compound up to 30 nucleobases in length targeted to the coding region, or start site of a nucleic acid molecule encoding focal adhesion kinase, wherein said antisense compound inhibits the expression of said focal adhesion kinase and has a sequence comprising at least an 8 nucleobasic portion of SEQ ID NO: 10, 11, 12, 14, 15, 30, 31 or 33.

### Claim 19 (depends on 18)

The antisense compound of claim 18 which is an antisense oligonucleotide.

### Claim 20 (depends on 19)

The antisense compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 21 (depends on 20)

The antisense compound of claim 20 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 22 (depends on 19)

The antisense compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 23 (depends on 22)

The antisense compound of claim 22 wherein the modified sugar moiety is a 2′-O-methoxyethyl moiety.

### Claim 24 (depends on 19)

The antisense compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 25 (depends on 24)

The antisense compound of claim 24 wherein the modified nucleobase is a 5-methyl cytosine.

### Claim 26 (depends on 19)

The antisense compound of claim 19 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 27 (depends on 18)

A pharmaceutical composition comprising the antisense compound of claim 18 and a pharmaceutically acceptable carrier or diluent.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27 further comprising a colloidal dispersion system.

### Claim 29 (depends on 27)

The pharmaceutical composition of claim 27 wherein the antisense compound is an antisense oligonucleotide.

### Claim 30 (depends on 27)

The pharmaceutical composition of claim 27 further comprising a chemotherapeutic agent.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30 wherein the chemotherapeutic agent is 5-fluorouracil.

### Claim 32 (depends on 30)

A method of inhibiting the growth of a tumor in an animal comprising administering to said animal an effective amount of the pharmaceutical composition of claim 30.

### Claim 33 (depends on 18)

A method of inhibiting the expression of focal adhesion kinase in cells or tissues comprising contacting said cells or tissue with the antisense compound of claim 18 so that expression of focal adhesion kinase is inhibited.

### Claim 34

A method of treating an animal having a disease or condition associated with focal adhesion kinase comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human focal adhesion kinase wherein said antisense compound inhibits the expression of human focal adhesion kinase.

### Claim 35 (depends on 34)

The method of claim 34 wherein the disease or condition is cancer.

### Claim 36 (depends on 35)

The method of claim 35 wherein said cancer is of the breast, colon, mouth or skin.

### Claim 37 (depends on 34)

The method of claim 34 wherein said disease or condition is an angiogenic disorder.

### Claim 38 (depends on 37)

The method of claim 37 wherein said angiogenic disorder is retinal neovascularization.

### Claim 39

A method of preventing migration of cells associated with expression of focal adhesion kinase comprising administering to said cells a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human focal adhesion kinase wherein said antisense compound inhibits the expression of human focal adhesion kinase.

### Claim 40

A method of preventing neovascularization associated with expression of focal adhesion kinase in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human focal adhesion kinase wherein said antisense compound inhibits the expression of human focal adhesion kinase.

### Claim 41

A method of treating an animal having a disease or condition associated with focal adhesion kinase comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human focal adhesion kinase in combination with a therapeutically or prophylactically effective amount of a chemotherapeutic agent.

### Claim 42 (depends on 41)

The method of claim 41 wherein the chemotherapeutic agent is 5-fluorouracil.

### Claim 43 (depends on 41)

The method of claim 41 wherein the disease or condition is cancer.

### Claim 44 (depends on 43)

The method of claim 43 wherein said cancer is melanoma.
